Core Viewpoint - Rosen Law Firm is urging investors of Neumora Therapeutics, Inc. to secure legal counsel before the April 7, 2025 deadline for a securities class action related to the company's IPO in September 2023 [1][2]. Group 1: Legal Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that the Offering Documents contained false or misleading statements, including the necessity for Neumora to amend trial criteria to justify its Phase Three Program [5]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [5].

DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend the original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ("MDD") to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) ...

NEW YORK, March 30, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. Follow us for updates ...

If you suffered Neumora losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/neumora-therapeutics-inc? utm_source=PR&utm_medium=link&utm_campaign=nma&mktm=r You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Neumora Therapeutics, Inc. about the April 7, 2025 deadline to join a securities class action lawsuit related to the company's September 2023 IPO [1][2]. Group 1: Class Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that the Offering Documents contained false or misleading statements, including the necessity for Neumora to amend trial criteria to justify its Phase Three Program [5]. - It is claimed that Neumora added a prespecified analysis to the Phase Two statistical analysis plan to focus on patients with moderate to severe major depressive disorder [5]. - The lawsuit also states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, impacting the predictability of the KOASTAL-1 study results [5].

NEW YORK, March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or tr ...

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/ ...

NEW YORK, March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=138813&from=4CLASS PERIOD: ...

RADNOR, Pa., March 26, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the "Offering Documents") issued in connection with Neumora's initial public offering held on or aro ...

LOS ANGELES, March 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA) investors of a class action representing investors who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commencing on or about September 15, 2023. Neumora investors have until April 7, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-888 ...